Form 4: Immuneering Director Diana Hausman Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Diana Hausman was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.
Summary
- Director Diana Hausman acquired 33,350 stock options in Immuneering Corp (IMRX).
- The options have an exercise price of $4.12 per share.
- The grant date for these derivative securities is June 11, 2026.
- The options are set to expire on June 11, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- Results in potential future dilution of existing shareholders upon exercise of the options.
Risks
- Market volatility affecting the value of the underlying Class A Common Stock.
- Potential for the stock price to remain below the $4.12 exercise price, rendering the options underwater.
Future Outlook
The options vest in equal monthly installments over a one-year period, ensuring continued service and alignment with company performance through June 2027.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while maintaining cash reserves.
Comparison to Industry Standards
- The use of time-based vesting over one year is consistent with standard corporate governance practices for board members in small-cap biotech firms.
- The grant size is typical for director compensation packages in companies of similar market capitalization.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of stock options to a member of the Board of Directors. | 06/11/2026 | Standard alignment of director incentives with company performance. |
Stakeholder Impact
- Shareholders: Potential for minor dilution upon future exercise of options.
- Director: Increased financial stake in the company's long-term performance.
Next Steps
- Vesting of options to commence on July 11, 2026.
- Full vesting expected by June 11, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/11/2026 | Transaction date of the stock option grant. |
| 07/11/2026 | Commencement date for the monthly vesting schedule. |
| 06/11/2027 | Full vesting date or date of the 2027 annual meeting, whichever is earlier. |
| 06/11/2036 | Expiration date of the stock options. |
Keywords
Immuneering, IMRX, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.